Guidelines to cell engineering for monoclonal antibody production.
Monoclonal antibodies (mAbs) are currently used for many diagnostic and therapeutic applications. The high demand for these biopharmaceuticals has led to the development of large-scale manufacturing processes, with productivity improvements being mainly achieved by optimization of bioreactor systems. However, more recently, the early steps of production, previous to bioreactor culture, have been presented as alternative areas where productivity enhancements can be achieved. Thus, this review describes the progress made for the improvement of productivity in mammalian expression systems for the high production of mAbs. Advances in the development of mAb-producing cell lines are being made, particularly regarding expression vector design and methods used for transfection, with the intent to create a reproducible methodology. Selection of the most suitable clones is also a critical step that can be improved, by including variables other than the expression level, which is still the common practice. Furthermore, strategies of cell engineering, although still mostly based on trial-and-error experimentation and not in standard protocols, hold great interest to improve cell growth and productivity, as well as product quality in the future. Improvements of the initial steps of the production process would not only result in cells with higher expression ability, but would also speed-up the process development.
IBB - Institute for Biotechnology and Bioengineering, University of Minho, Braga, Portugal.
A
A
Rita Costa
M
M
Elisa Rodrigues
Mariana
M
Henriques
Joana
J
Azeredo
Rosário
R
Oliveira
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis*; D001709:Biotechnology / Q000639:trends*; D018929:Cell Culture Techniques / Q000379:methods; D006801:Humans; D015202:Protein Engineering / Q000379:methods*; D013678:Technology, Pharmaceutical / Q000379:methods; D014162:Transfection / Q000379:methods*
D000911:Antibodies, Monoclonal